ADVERTISEMENT

Issue Navigator

Volume 13 No. 03
Earn CME
Accepted Papers
Classifieds







Scientific Investigations

Circulating Anti-Coatomer Protein Complex Subunit Epsilon (COPE) Autoantibodies as a Potential Biomarker for Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea

http://dx.doi.org/10.5664/jcsm.6488

Takuma Matsumura, MD1; Jiro Terada, MD, PhD1; Taku Kinoshita, MD1; Yoriko Sakurai, MD, PhD1; Misuzu Yahaba, MD, PhD1; Ryogo Ema, MD1; Atsuko Amata, MD1,2; Seiichiro Sakao, MD, PhD1; Kengo Nagashima, PhD3; Koichiro Tatsumi, MD, PhD1; Takaki Hiwasa, PhD4
1Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Department of Medicine, Nikko Memorial Hospital, Hitachi, Japan; 3Department of Global Clinical Research, Graduate School of Medicine, Chiba University, Chiba, Japan; 4Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan

Study Objectives:

Although moderate to severe obstructive sleep apnea (OSA) is an independent risk factor for severe arteriosclerotic diseases such as cardiovascular disease (CVD) and stroke, the development of atherosclerosis-related diseases cannot yet be predicted in patients with OSA. In a pilot study, we identified autoantibodies against the coatomer protein complex, subunit epsilon [circulating anti-coatomer protein complex subunit epsilon autoantibody (COPE-Ab)], a cytosolic complex that mediates protein transport in the Golgi compartment, as a potential novel biomarker of atherosclerosis. This study aimed to evaluate whether COPE-Ab levels had an association with cardiovascular and cerebrovascular events in patients with OSA.

Methods:

Eighty-two adult patients with a diagnosis of OSA via polysomnography and 64 healthy donors were studied. Serum COPE-Ab levels were measured using an amplified luminescence proximity homogeneous assay. Then, clinical factors related to atherosclerosis were evaluated with respect to COPE-Ab levels.

Results:

Significant differences in COPE-Ab levels were observed in terms of OSA severity. COPE-Ab levels were significantly higher in patients with OSA and also CVD and/or stroke, hypertension, and a high body mass index. Univariate and multivariate logistic regression analyses of patients with OSA identified elevated COPE-Ab level as a significant predictor of CVD and/or stroke.

Conclusions:

An elevated COPE-Ab level may be a potential predictor of the risks of cardiovascular and cerebrovascular events in patients with OSA. Therefore, patients with higher COPE-Ab levels may require more careful and intensive treatment.

Commentary:

A commentary on this article appears in this issue on page 361.

Citation:

Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K, Tatsumi K, Hiwasa T. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardiovascular and cerebrovascular events in patients with obstructive sleep apnea. J Clin Sleep Med. 2017;13(3):393–400.




Please login to continue reading the full article

Subscribers to JCSM get full access to current and past issues of the JCSM.

Login to JCSM

Not a subscriber?

Join the American Academy of Sleep Medicine and receive a subscription to JCSM with your membership